Progyny, Inc. (PGNY) Stock Price & How to Invest

Progyny sells a carve-out fertility benefit to self-insured employers. Rather than a dollar cap or a cycle cap, clients buy bundles that Progyny calls Smart Cycles, delivered through a credentialed network of fertility clinics, with an in-house team of care advocates guiding members through treatment. Progyny Rx, the attached specialty pharmacy solution, handles the medications and accounts for roughly a third of revenue. The company launched with five clients in 2016 and had ~604 fertility and family building clients as of June 30, 2026, covering ~7.2 million lives at employers ranging from ~1,000 to ~300,000 employees. It has since extended the same benefits-management model into pregnancy and postpartum, menopause and midlife, leave navigation and parent and child wellbeing, all sold into the same HR buyer.

The financial picture in late 2026 is a business growing single digits on the headline and low double digits underneath. Q2 2026 revenue was ~$350.5 million, up ~5.3% year over year, or ~11% once you strip out the ~$17.2 million contributed in the prior-year quarter by a very large client that did not renew for 2025. Gross margin widened to ~25.5% from ~23.7%, net income nearly doubled to ~$28.1 million, and the share count has fallen from ~83.4 million to ~77.4 million as two $200 million repurchase programs ran. EPS of ~$0.55 beat the ~$0.52 consensus, the fourth straight beat. The stock still fell ~7% on August 7, 2026 to ~$28.10, because third quarter guidance embeds a more pronounced summer lull in member activity, and it traded at ~$27.22 on October 16, 2026, about 16% below its level three months earlier. On October 7 the company said the 2027 selling season is pacing to a potential record, with commitments received to date and anticipated remaining decisions expected to add ~1.2 million new covered lives during the first half of 2027; the shares rose about 6% on the news. That is the tension worth understanding: an employer benefit with high retention and a real network advantage, priced against the memory of one client departure that erased several points of growth for two years running.

Client concentration is the structural risk: contracts run three years but carry termination options after year one on 30 to 90 days' notice, and the departure of one large client removed ~$48.5 million of 2025 revenue and suppressed reported growth through the first half of 2026. Utilization is not under management's control, and a soft engagement year would flow almost directly to the top line because the recurring population fee is only ~1% of revenue. Gross margin of ~25.5% is thin by software standards because Progyny passes through clinic and pharmacy costs, so an adverse shift in treatment or drug mix compresses operating income faster than revenue implies. Competitively, health plans and pharmacy benefit managers can fold a fertility rider into a contract the employer already signed, and venture-funded specialists compete on price in the same RFPs. Reproductive-health politics adds a further layer, since state-level rulings on embryos and any change to federal IVF coverage rules can reshape both demand and the cost of delivering care. The October 2026 selling-season figure is a forecast built partly on decisions not yet made, and newly added lives tend to ramp utilization gradually, so the revenue impact in 2027 may lag the headline lives count.

12 analysts publish price targets on PGNY, averaging $34.42 against a $29.49 price as of November 2026, or +16.7%. The published targets run from $30.00 to $40.00, a narrow spread, and the ratings split 10 buy, 2 hold, 0 sell. Over the last six months there have been 9 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PGNY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Progyny, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Client wins and covered lives. Progyny ended Q2 2026 with ~604 fertility and family building clients, up from ~542 a year earlier, and average members of ~7.19 million versus ~6.74 million. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Client concentration is the structural risk: contracts run three years but carry termination options after year one on 30 to 90 days' notice, and the departure of one large client removed ~$48.5 million of 2025 revenue and suppressed reported growth through the first half of 2026. The most pessimistic target, $30.00, is roughly what PGNY is worth if this bites instead.

Read the full bull and bear case on PGNY, including what would have to change to break either one. Walnut is not an investment adviser.

No. Progyny, Inc. (PGNY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Progyny, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.31 billion; Q2 2026 ~$350.5 million, +5.3% yoy (~11% ex the lost client)
• Clients and covered lives: ~604 clients and ~7.2 million covered lives (June 30, 2026); ~1.2 million new lives expected in 1H 2027
• Profitability (TTM): ~$79 million GAAP net income (~6% margin), ~$201 million operating cash flow
• EPS (Q2 2026 vs estimate): ~$0.55 vs ~$0.52
• FY2026 guidance: revenue of ~$1.360 billion to ~$1.385 billion, adjusted diluted EPS of ~$2.04 to ~$2.10
• P/E (trailing GAAP / forward): ~30x / ~12x
• Market value and balance sheet: ~$2.1 billion market cap at ~$27.22 (52-week range ~$16.10 to ~$33.06), ~$237 million in cash and securities, ~$27 million of debt

At ~$27 the shares carry roughly 30x trailing GAAP earnings but about 12x forward adjusted estimates, because GAAP results still absorb stock compensation. Because Progyny passes clinic and pharmacy costs through, price-to-sales of ~1.6x understates the real multiple; EV to EBITDA is about 15x. Analysts expect revenue growth of about 10% in 2026 and 11% in 2027, which the October selling-season update supports but has not yet proven; the Q3 report on November 5 (consensus EPS ~$0.51 on ~$341 million of revenue) is the next data point.

Other names that sit close to PGNY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

There are three common ways to get PGNY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PGNY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PGNY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Progyny is a cash generative benefits manager whose year is decided by client wins and member utilization rather than by anything management can steer inside a single quarter. The October 2026 selling-season update, which pointed to about 1.2 million new covered lives launching in the first half of 2027, is the clearest read yet on next year's client side, and Q3 results follow on November 5.

Whether PGNY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PGNY a buy or a sell?, and where the stock could go from here in the PGNY stock forecast.

For income investors, whether PGNY pays a dividend and how the payout looks is covered in does PGNY pay a dividend? And to weigh PGNY against a peer, read the full side-by-side comparisons: PGNY vs UNH and PGNY vs ELV.